iver perfusion measurement using PCD-CT to characterize and evaluate the response to treatment of hepatocellular carcinomas of the liver as part of routine CT diagnostics and comparison with MRI liver diagnostics

niversitätsklinik Tübingen0 个研究点目标入组 100 人开始时间: 2023年5月15日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Patients with liver cirrhosis and HCC-suspect liver lesions (mainly hepatocellular carcinoma) who are before/during/after curative or palliative (systemic) therapy and patients who are about to have a liver transplant and therefore need the exclusion of HCC-suspicious lesions.
•The patient's willingness to cooperate, in particular an adequate understanding of the German language.
•Unrestricted ability of the patient to consent.
•Information about the study nature of the investigation
•Willingness to participate in the study, which is confirmed by signature
•Written declaration of consent to perform a computed tomography
•A GFR greater than 60 mL/min. According to the current state of knowledge, the application of iodinated contrast medium to patients with a GFR > 60 ml/min is considered harmless

•Patients with biguanide therapy (metformin in diabetes mellitus)
•past allergic reaction to non-ionic contrast media
•Pregnancy and breastfeeding women (due to the underlying disease of the patient group to be examined (tumor disease), pregnancy should be considered unlikely. However, this is also supported by questioning the patient. For safety reasons, a pregnancy test is carried out in every questionable case).
•extreme obesity (body diameter > diameter of the examination opening in the CT; currently permitted body weight 150 kg)
•Multiple myeloma
•known claustrophobia
•Manifest/latent hyperthyroidism (TSH basal < 0.2 mU/l and increase in peripheral thyroid values)
•Severe hepatic impairment (GOT, GPT > 3 times normal)
•Heart failure NYHA III-IV stage.
•Missing written declaration of consent.
•Age: < 18 years.

发起方

niversitätsklinik Tübingen